Estland - estisk - Ravimiamet

accord healthcare b.v. - oksaliplatiin - infusioonilahuse kontsentraat - 5mg 1ml 10ml 1tk; 5mg 1ml 40ml 1tk; 5mg 1ml 20ml 1tk

Estland - estisk - Ravimiamet

teva b.v. - oksaliplatiin - infusioonilahuse kontsentraat - 5mg 1ml 40ml 1tk; 5mg 1ml 10ml 1tk; 5mg 1ml 20ml 1tk; 5mg 1ml 4ml 1tk

Den europeiske union - estisk - EMA (European Medicines Agency)

eisai gmbh - lenvatinibmesülaat - kartsinoom, neerurakk - antineoplastilised ained - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

Den europeiske union - estisk - EMA (European Medicines Agency)

eisai gmbh - lenvatinibmesülaat - kilpnäärme kasvajad - antineoplastilised ained - lenvima on näidustatud monotherapy raviks täiskasvanud patsientidel, kellel on progresseeruv, lokaalselt kaugelearenenud või metastaatilise, liigendatud (papillary/follikulaarne/hürthle cell) kilpnäärme kartsinoom (dtc), rasksulavad, et radioaktiivse joodi (rai). lenvima on näidustatud monotherapy raviks täiskasvanud patsientidel, kaugelearenenud või unresectable hepatotsellulaarne kartsinoom (hcc), kes on saanud ilma eelneva süsteemse ravi.

Den europeiske union - estisk - EMA (European Medicines Agency)

ablynx nv - caplacizumab - purpur, tromboosi thrombocytopenic - antitrombootilised ained - cablivi on näidustatud ravi täiskasvanud kogevad episoodi omandatud tromboosi thrombocytopenic purpur (attp), koos plasma vahetus ja immunosupressiooni.

Den europeiske union - estisk - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - kartsinoom, squamous cell - antineoplastilised ained - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Estland - estisk - Ravimiamet

stada arzneimittel ag - ibuprofeen+fenüülefriin - õhukese polümeerikattega tablett - 400mg+10mg 24tk; 400mg+10mg 20tk; 400mg+10mg 10tk; 400mg+10mg 16tk; 400mg+10mg 12tk

Estland - estisk - Ravimiamet

mylan pharmaceuticals limited - alendroonhape+kolekaltsiferool - tablett - 70mg+2800rÜ 12tk; 70mg+2800rÜ 4tk

Estland - estisk - Ravimiamet

viatris healthcare limited - flurbiprofeen - suuõõnesprei, lahus - 2,5mg 1ml 15ml 1tk

Estland - estisk - Ravimiamet

mylan pharmaceuticals limited - alendroonhape+kolekaltsiferool - tablett - 70mg+5600rÜ 12tk